Press Releases

No. 40 | 24. September 2016 | by Koh

Michael Baumann, a Dresden cancer specialist, will be the new scientific director of the German Cancer Research Center.

Prof. Michael Baumann
© Philip Benjamin/NCT Dresden

The board of trustees at the German Cancer Research Center (DKFZ) in Heidelberg has unanimously elected Prof. Michael Baumann as chairman and scientific director of the German Cancer Research Center. Over the past years, Michael Baumann has proven to be a successful physician, cancer researcher and science manager. He has worked as the director of Radiation Therapy at the University Hospital Carl Gustav Carus, the Institute for Radiation Oncology at the Helmholtz-Center in Dresden-Rossendorf and the OncoRay-Center. The employment contract has been signed, allowing Michael Baumann to move to the German Cancer Research Center, that he will lead together with administrative director Prof. Josef Puchta, as of November 1, 2016.

Michael Baumann will step in as the successor to Prof. Michael Boutros, who temporarily held the office of Prof. Otmar D. Wiestler. Prof. Wiestler took over the position as President of the Helmholtz-Association in Berlin on September 1, 2015.

read more

No. 39 | 20. September 2016 | by HC/Sel

Liquid Biopsy: Level of mutated DNA in the blood corresponds to patient outcome

© Photograph by Graham Beards, distributed under a CC BY-SA 3.0 and present on Wikimedia Commons.

New findings from a scientific collaboration between the German Cancer Research Center (DKFZ), the National Center for Tumor Diseases (NCT) Heidelberg and the Thoraxklinik Heidelberg suggest liquid biopsy as a promising tool to monitor lung cancer patient tumors early. Scientists associated liquid biopsy readouts with clinical data and were able to track tumor responses to cancer drugs in real-time. Their paper has just been published in the latest issue of Scientific Reports.

read more

No. 36 | 13. September 2016 | by Sel

Lasker Award for Ralf Bartenschlager

© dkfz / Tobias Schwerdt

Ralf Bartenschlager, Virologist and cancer researcher at the Heidelberg University Hospital and the German Cancer Research Center (DKFZ) has received the Lasker-DeBakey Medical Research Award endowed with 250 000 Dollar. This prize, which is awarded annually in three categories by the Lasker Foundation in New York, is the highest distinction for medical science in the USA. Many prize winners have later gone on to receive the Nobel Prize. Bartenschlager and his group were the first to propagate the hepatitis C virus in the lab. This has made it possible to develop targeted therapies against the virus that can lead to chronic infection and cirrhosis or cancer of the liver.

read more

No. 34 | 07. September 2016 | by Koh

Medication against schizophrenia inhibits pancreatic cancer

A pancreatic cancer cell. The nucleus is stained blue, the fibers of the cy...
© Dr. Nathalie Giese, Chirurgische Universitätsklinik Heidelberg

Scientists from the German Cancer Research Center (DKFZ), Heidelberg, and from McGill University, Montreal, Canada, have discovered that a receptor for the dopamine neurotransmitter promotes growth and spread of pancreatic cancer. Medications against schizophrenia, which block the function of this receptor, slowed down tumor growth and metastatic spread in mice.

read more

No. 33 | 31. August 2016 | by Sel

Changeover in the Cancer Prevention Unit: Ute Mons is taking over from Martina Pötschke-Langer

Changeover in the Cancer Prevention Unit: Ute Mons (left) is taking over fr...
© Jutta Jung/DKFZ

On September 1, 2016 Dr. Ute Mons will take over as Head of the Cancer Prevention Unit at the German Cancer Research Center, which also serves as the WHO Collaboration Center for Tobacco Control. She will be replacing Dr. Martina Pötschke-Langer, who headed the unit since it was established 19 years ago, and is now retiring.

read more

No. 33c | 31. August 2016

DKTK Dresden: CRISPR/Cas9 technology to diagnose cancer mutations

The genome scissor CRISPR/Cas9 can help to distinguish mutations that drive...
© Frank Buchholz, Dresden

As for many other biomedical and biotechnology disciplines, the genome scissor "CRISPR/Cas9" also opens up completely new possibilities for cancer research. Scientists of the National Center for Tumor Disease (NCT), the German Cancer Consortium (DKTK) and the Medical Faculty of the TU Dresden have shown that mutations that act as cancer drivers can be targeted and repaired. The most relevant mutations could therefore be diagnosed faster, improving personalized therapies.
The National Center for Tumor Diseases (NCT) Dresden is a joint institution of the German Cancer Research Center (DKFZ) in Heidelberg, the University Hospital Carl Gustav Carus Dresden, the Medical Faculty of the TU Dresden and the Helmholtz-Zentrum Dresden-Rossendorf. The German Cancer Consortium (DKTK) builds a strong, long-term, institutional structure between the DKFZ and universities and university hospitals all over Germany specially designated to clinical oriented cancer research.

read more

No. 32c | 25. August 2016

Preventing obesity – preventing cancer!

Prof. Rudolf Kaaks
© Tobias Schwerdt/DKFZ

Cancer can be prevented by preventing obesity: Experts from the International Agency for Research on Cancer (IARC) have re- evaluated available data for the new edition of the Handbook of Cancer Prevention. Rudolf Kaaks from the German Cancer Research Center (DKFZ) has made major contributions to the current evaluation.

read more

No. 31 | 23. August 2016 | by Koh

Low-protein diet enhances glucose metabolism

In mice and men, a low protein diet leads to lower blood glucose and insuli...
© Wikimedia Commons/Olearys

Scientists at the German Cancer Research Center (DKFZ) have shown in mice that a low-protein diet increases fat and carbohydrate burning, thus raising energy expenditure. Changing the animals' diet to low-protein intake even led to the regression of insulin resistance – independent of their body weight and total energy intake. A temporary low-protein diet also lowered insulin and glucose levels in young human volunteers. This effect is regulated by a central stress response by liver cells.

read more

No. 28 | 12. August 2016

Drug against psoriasis slows down cancer cell growth and metastasis

Immunofluorescence of a cutaneous T cell lymphoma after treatment with DMF ...
© Blood, Photo: Anne Schröder/Karin Müller-Decker

Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) are examining a promising agent against cancer of the immune system. In this type of cancer, the tumor cells have lost their ability to respond to signals that cause programmed cell death, or apoptosis. The new substance restores this ability, thus slowing down tumor growth and, above all, metastatic spread.

read more

No. 27c2 | 08. August 2016

One million € funding for the development of norovirus therapeutics

Electron micrograph of norovirus virus-like particles (VLPs) and a cartoon ...
© Dr. Grant Hansman, DKFZ

Grant Hansman, head of the CHS Research Group noroviruses, has raised funding under the BMBF funding program "Validation of the Technological and Social Innovation Potential of Scientific Research" in the amount of € 1,164,000. Hansman will develop new antiviral Nanobodies in the project, which can be used as a norovirus therapeutics and diagnostics.

read more


Subscribe to our RSS-Feed.

to top